Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease

被引：8

作者：

Chen, Huanhua ^{[1
]}

Gao, Xudong ^{[3
]}

Li, Xinzhu ^{[2
]}

Yu, Chong ^{[1
]}

Liu, Wenwu ^{[1
]}

Qiu, Jingsong ^{[1
]}

Liu, Wenjie ^{[1
]}

Geng, Hefeng ^{[2
]}

Zheng, Fangyuan ^{[2
]}

Gong, Hao ^{[1
]}

Xu, Zihua ^{[1
]}

Jia, Jingming ^{[1
]}

Zhao, Qingchun ^{[1
,2
,3
]}

机构：

[1] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Liaoning, Peoples R China

[2] Shenyang Pharmaceut Univ, Sch Life Sci & Biochem, Shenyang 110016, Liaoning, Peoples R China

[3] Gen Hosp Northern Theater Command, Dept Pharm, Shenyang 110840, Peoples R China

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 15期

基金：

中国国家自然科学基金;

关键词：

GLYCOGEN-SYNTHASE KINASE-3; SPATIAL MEMORY IMPAIRMENT; DOWN-SYNDROME; TAU-PHOSPHORYLATION; DYRK1A INHIBITOR; DRUG DISCOVERY; PROTEIN; MECHANISM; SUPPORT; RESCUES;

D O I：

10.1021/acs.jmedchem.4c00483

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has been verified to regulate the progression of tau pathology as a promising treatment for Alzheimer's disease (AD), while the research progress on DYRK1A inhibitors seemed to be in a bottleneck period. In this work, we identified 32 (ZJCK-6-46) as the most potential DYRK1A inhibitor (IC50 = 0.68 nM) through rational design, systematic structural optimization, and comprehensive evaluation. Compound 32 exhibited acceptable in vitro absorption, distribution, metabolism, and excretion (ADME) properties and significantly reduced the expression of p-Tau Thr212 in Tau (P301L) 293T cells and SH-SY5Y cells. Moreover, compound 32 showed favorable bioavailability, blood-brain barrier (BBB) permeability, and the potential of ameliorating cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo, which was deserved as a valuable molecular tool to reveal the role of DYRK1A in the pathogenesis of AD and to further promote the development of anti-AD drugs.

引用

页码：12571 / 12600

页数：30

共 65 条

[31] Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease [J].

Liu, Wenwu ;

Liu, Xin ;

Liu, Wenjie ;

Gao, Yaping ;

Wu, Limeng ;

Huang, Yaoguang ;

Chen, Huanhua ;

Li, Deping ;

Zhou, Lijun ;

Wang, Nan ;

Xu, Zihua ;

Jiang, Xiaowen ;

Zhao, Qingchun .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 229

[32] Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease [J].

Liu, Wenwu ;

Liu, Xin ;

Tian, Liting ;

Gao, Yaping ;

Liu, Wenjie ;

Chen, Huanhua ;

Jiang, Xiaowen ;

Xu, Zihua ;

Ding, Huaiwei ;

Zhao, Qingchun .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 222

[33] An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease [J].

Liu, Xin ;

Lai, Ling-yun ;

Chen, Jiang-xia ;

Li, Xiang ;

Wang, Nan ;

Zhou, Li-jun ;

Jiang, Xiao-wen ;

Hu, Xiao-long ;

Liu, Wen-wu ;

Jiao, Xin-ming ;

Qi, Zhen-tong ;

Liu, Wen-jie ;

Wu, Li-meng ;

Huang, Yao-guang ;

Xu, Zi-hua ;

Zhao, Qing-chun .

NEUROPHARMACOLOGY, 2023, 232

[34] Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133 [J].

Liu, Yahu A. ;

Jin, Qihui ;

Zou, Yefen ;

Ding, Qiang ;

Yan, Shanshan ;

Wang, Zhicheng ;

Hao, Xueshi ;

Bao Nguyen ;

Zhang, Xiaoyue ;

Pan, Jianfeng ;

Mo, Tingting ;

Jacobsen, Kate ;

Thanh Lam ;

Wu, Tom Y-H ;

Petrassi, H. Michael ;

Bursulaya, Badry ;

DiDonato, Michael ;

Gordon, W. Perry ;

Liu, Bo ;

Baaten, Janine ;

Hill, Robert ;

Van Nguyen-Tran ;

Qiu, Minhua ;

Zhang, You-Qing ;

Kamireddy, Anwesh ;

Espinola, Sheryll ;

Deaton, Lisa ;

Ha, Sukwon ;

Harb, George ;

Jia, Yong ;

Li, Jing ;

Shen, Weijun ;

Schumacher, Andrew M. ;

Colman, Karyn ;

Glynne, Richard ;

Pan, Shifeng ;

McNamara, Peter ;

Laffitte, Bryan ;

Meeusen, Shelly ;

Molteni, Valentina ;

Loren, Jon .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (06) :2958-2973

[35] Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease [J].

Maqbool, Mudasir ;

Mobashir, Mohammad ;

Hoda, Nasimul .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 107 :63-81

[36] Metabolic stability for drug discovery and development - Pharmacokinetic and biochemical challenges [J].

Masimirembwa, CM ;

Bredberg, U ;

Andersson, TB .

CLINICAL PHARMACOKINETICS, 2003, 42 (06) :515-528

[37] Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease [J].

Melchior, Benoit ;

Mittapalli, Gopi Kumar ;

Lai, Carolyn ;

Duong-Polk, Karen ;

Stewart, Joshua ;

Guner, Bora ;

Hofilena, Brian ;

Tjitro, Amanda ;

Anderson, Scott D. ;

Herman, David S. ;

Dellamary, Luis ;

Swearingen, Christopher J. ;

Sunil, K. C. ;

Yazici, Yusuf .

AGING CELL, 2019, 18 (05)

[38] Effective handling of induced-fit motion in flexible docking [J].

Mizutani, Miho Yamada ;

Takamatsu, Yoshihiro ;

Ichinose, Tazuko ;

Nakamura, Kensuke ;

Itai, Akiko .

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2006, 63 (04) :878-891

[39] A method for induced-fit docking, scoring, and ranking of flexible ligands.: Application to peptidic and pseudopeptidic β-secretase (BACE 1) inhibitors [J].

Moitessier, Nicolas ;

Therrien, Eric ;

Hanessian, Stephen .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (20) :5885-5894

[40] Neuroprotective effects of donepezil against Aβ42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3β and nAChRs activity [J].

Noh, Min-Young ;

Koh, Seong H. ;

Kim, Sung-Min ;

Maurice, Tangui ;

Ku, Sae-Kwang ;

Kim, Seung H. .

JOURNAL OF NEUROCHEMISTRY, 2013, 127 (04) :562-574

← 1 2 3 4 5 6 7 →